Chronic Lymphocytic Leukemia

Voxtalisib (XL765) monotherapy induced objective responses in 41.3% of patients with follicular lymphoma, but displayed minimal efficacy in patients with other lymphomas, according to results from a phase II trial of patients with relapsed or refractory lymphoma or chronic lymphocytic leukemia that were recently published in the Lancet Haematology.

<em>Targeted Oncology</em>&trade;, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 30. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field.

Venetoclax induced a response in two-thirds of patients with relapsed/refractory chronic lymphocytic leukemia who had progressed after receiving prior therapy with idelalisib, according to findings of a phase II study recently published in <em>Blood</em>.

Jacqueline C. Barrientos, MD, associate professor of the Karches Center for Oncology Research at the Feinstein Institute for Medical Research, discusses which types of patients with chronic lymphocytic leukemia are the best candidates for treatment with ibrutinib

According to preliminary results of a phase II trial, the combination of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) is a safe initial therapy for treatment-na&iuml;ve patients with chronic lymphocytic leukemia (CLL).

According to Neil E. Kay, MD, novel agents,&nbsp;such as&nbsp;ibrutinib (Imbruvica), venetoclax (Venclexta), idelalisib (Zydelig), and acalabrutinib (Calquence), are revolutionizing treatment for patients with chronic&nbsp;lymphocytic leukemia. However, the best way to sequence these agents to maximize the benefit to patients is still unclear.

A new drug application seeking a full approval for duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma has been granted a priority review by the FDA.

The treatment paradigm of chronic lymphocytic leukemia continues to advance, with many ongoing clinical trials investigating combinations seeking to build upon the success seen with Bruton&rsquo;s tyrosine kinase inhibitors. Such potential combination therapies for CLL include venetoclax (Venclexta) with either ibrutinib (Imbruvica) or acalabrutinib (Calquence).

According to findings from the phase III MURANO trial recently published in the<em> New England Journal of Medicine, </em>the venetoclax&nbsp;(Venclexta) plus rituximab&nbsp;(Rituxan) regimen lowered the risk of disease progression or death by 83% in comparison with bendamustine (Treanda) plus rituximab&nbsp;(Rituxan) in patients with relapsed or refractory chronic lymphocytic leukemia<em>.</em>

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the phase III DUO trial, a randomized comparison of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia.

According to phase I findings published in <em>The Lancet Oncology,</em>&nbsp;an&nbsp;objective response rate of 37% was induced in patients with&nbsp;relapsed/refractory lymphoma or chronic lymphocytic leukemia treated with the&nbsp;PI3K-delta inhibitor umbralisib.

The clinical course of chronic lymphocytic leukemia is highly variable, and a subset of patients may never need clinical intervention. However, most patients will eventually require treatment during their disease.

Susan O&rsquo;Brien, MD,&nbsp; discusses the tremendous impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies and highlights where this regimen is headed in the future of treatment for patients with CLL.